Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Authors :: Cem Akin
Frank Siebenhaar
Michael W. Deininger
Daniel J. DeAngelo
Tracy I. George
Mariana Castells
Matthew Giannetti
Jason Gotlib
Jessica Sachs
Amanda Pilla
Hina A. Jolin
Prithviraj Bose
Source :: Blood. 140:6838-6839
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools